Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 25, 2025 08:00 ET | Source: UroGen Pharma Ltd.

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...
November 06, 2025 07:58 ET | Source: UroGen Pharma Ltd.

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...
November 04, 2025 08:00 ET | Source: UroGen Pharma Ltd.

UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference

PRINCETON, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...
October 31, 2025 10:01 ET | Source: Urology Care Foundation

Behind the Bathroom Door: Urology Care Foundation Flushes Out Myths for Bladder Health Month

BALTIMORE, Oct. 31, 2025 (GLOBE NEWSWIRE) -- November is Bladder Health Month, and the Urology Care Foundation (UCF), the official foundation of the American Urological Association, is lifting the...
October 30, 2025 13:16 ET | Source: Research and Markets

Bladder Cancer Market - Global and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson

Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The "Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The...
October 30, 2025 08:00 ET | Source: UroGen Pharma Ltd.

UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...
October 21, 2025 10:03 ET | Source: Urology Care Foundation

Urology Care Foundation Announces Recipient of the 2025 Rising Stars in Urology Research Award

BALTIMORE, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) and the Urology Care Foundation (UCF)—the official foundation of the AUA—today announced Filipe de Carvalho,...
October 02, 2025 08:00 ET | Source: UroGen Pharma Ltd.

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

Reviews in Urology literature review of ZUSDURI (UNG-102) clinical trial program including ENVISION, OPTIMA II and the ATLAS clinical trials
September 29, 2025 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer

KNOXVILLE, Tenn., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the start of a preclinical study of its lead...
September 12, 2025 08:30 ET | Source: Biodexa Pharmaceuticals PLC

Interim results for the six months ended June 30, 2025

September 12, 2025 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage...